Pasar al contenido principal

INMUNOTERAPIA CONTRA TUMORES HER2 POSITIVOS

PI19/01181

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización FUNDACION PRIVADA INSTITUTO DE INVESTIGACION ONCOLOGICA VALLE DE HEBRON- VHIO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Grinyó-Escuer, Ariadna|||0000-0003-0185-2734
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Rius-Ruiz, Irene
  • Bort-Brusca, Marta
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Maqueda-Marcos, Susana
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Gago, Judit
  • Nogales, Vanesa
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Peg, Vicente|||0000-0002-5203-6166
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Soucek, Laura|||0000-0002-4750-7971
  • Braña, Irene|||0000-0002-1068-9601
  • Galvao, Vladimir
  • Martín-Lluesma, Silvia|||0000-0001-7491-1876
  • Moessner, Ekkehard
  • Klein, Christian|||0000-0001-7594-7280
  • Garralda, Elena|||0000-0002-4412-7842
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors. Chimeric antigen receptor T (CAR-T) cell therapy is efficient in certain haematologic malignancies, but clinical success in solid tumours has been hampered by scarcity of tumour-specific antigens. Here authors show that combination therapy using CAR T cells targeting p95HER2 and bispecific antibodies against HER2 and CD3 consistently leads to complete regression in HER2-positive, patient-derived xenografts tumours in mouse models.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • ADAM-ARTIGUES, ANNA
  • Brasó-Maristany, Fara
  • Cervera Vidal, Raimundo
  • Tormo, Eduardo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
Breast cancer; Heterodimerization, Cáncer de mama; Heterodimerización, Càncer de mama; Heterodimerització, Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer., A.A.-A., E.J.A., and F.B.-M. were supported by Asociación Española contra el Cáncer AECC (PRDVA18013LLUC to A.A.-A., POSTD211413AREN to E.J.A., and AECC_Postdoctoral17-1062 to F.B.-M.). A.M.-S. was funded by the Spanish Government (PFIS FI20/00188). J.Ar. is supported by Breast Cancer Research Foundation (BCRF-20-08), Instituto de Salud Carlos III Project reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (AECC). A.P. was supported by Instituto de Salud Carlos III—PI19/01846, Breast Cancer Now—2018NOVPCC1294. P.E. and A.L. were funded by Instituto de Salud Carlos III and cofinanced by FEDER (PI18/01219 to P.E. and CB16/12/00481 to A.L.). J.M.C. was funded by Sociedad Española de Oncología Médica (Rio Hortega-SEOM) and Compromiso ADAMED.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

  • Gámez‑Chiachio, Manuel
  • Molina‑Crespo, Ángela
  • Ramos Nebot, Carmen
  • Martinez‑Val, Jeannette
  • Martinez, Lidia
  • Gassner, Katja
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
Gasdermin B; HER2 breast cancer; Protective autophagy, Gasdermin B; Càncer de mama HER2; Autofàgia protectora, Gasdermin B; Cáncer de mama HER2; Autofagia protectora, Background Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. Methods Different in vitro approaches (immunoblot, qRT-PCR, flow cytometry, proteomic analysis, immunoprecipitation, and confocal/electron microscopy) were performed in HER2 breast and gastroesophageal carcinoma cell models. Results were then validated using in vivo preclinical animal models and analyzing human breast and gastric cancer samples. Results GSDMB up-regulation renders HER2 cancer cells more resistant to anti-HER2 agents by promoting protective autophagy. Accordingly, the combination of lapatinib with the autophagy inhibitor chloroquine increases the therapeutic response of GSDMB-positive cancers in vitro and in zebrafish and mice tumor xenograft in vivo models. Mechanistically, GSDMB N-terminal domain interacts with the key components of the autophagy machinery LC3B and Rab7, facilitating the Rab7 activation during pro-survival autophagy in response to anti-HER2 therapies. Finally, we validated these results in clinical samples where GSDMB/Rab7/LC3B co-expression associates significantly with relapse in HER2 breast and gastric cancers. Conclusion Our findings uncover for the first time a functional link between GSDMB over-expression and protective autophagy in response to HER2-targeted therapies. GSDMB behaves like an autophagy adaptor and plays a pivotal role in modulating autophagosome maturation through Rab7 activation. Finally, our results provide a new and accessible therapeutic approach for HER2/GSDMB + cancers with adverse clinical outcome., This study has been supported by the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (PID2019-104644RB-I00) -GMB-, the Instituto de Salud Carlos III (CIBERONC, CB16/12/00449 -JA-, CB16/12/00231 -DLN- and CB16/12/00295 -GMB-, PI19/01181 -JA-, PI18/00795, CP17/00063 and RTI2018-095611-A-I00 -DLN- and ERA-NET TRANSCAN-2 -JA- [all partly supported by FEDER funds]) and by the AECC Scientific Foundation (FC_AECC PROYE19036MOR -GMB- and LABAE19004LLOB -DLN-). Furthermore, this work was supported by Breast Cancer Research Foundation (BCRF-19–08) -JA-. We are also grateful to the CERCA Programme (Generalitat de Catalunya) for institutional support. MGC and DS contracts are funded by CIBERONC, KG is a recipient of a PFIS fellowship (FI19/00188), RRB is recipient of a Ramón y Cajal grant (RyC-2016–19671) and DLN is recipient of a Miguel Servet grant (MS17/00063) (all partly supported by FEDER funds). We are also grateful to MD Anderson BIOBANK for providing tumor samples. The bank (reference # B.0000745) belongs to the National Registry of Biobanks coordinated by the Carlos III Health Institute.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

  • Chaib, Selim
  • Lopez-Dominguez, Jose Alberto
  • Lalinde Gutiérrez, Marta
  • Prats, Neus
  • Marin Guillen, Ines
  • Boix Sánchez, Olga
  • Pérez Ramos, Sandra
  • Escorihuela Baez, Marta
  • Garcia-Garijo, Andrea
  • Abad, Maria
  • Gros, Alena
  • Arribas, Joaquin
Chemotherapy; Intratumoral senescent cells, Quimioterapia; Células senescentes intratumorales, Quimioteràpia; Cèl·lules senescents intratumorals, Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence., We thank the IRB Core Facilities (Functional Genomics Core, Biostatistics/Bioinformatics and Histopathology), the Parc Científic de Barcelona Animal Facility and the University of Barcelona/Centros Científicos y Tecnológicos de la Universidad de Barcelona Flow Cytometry Facility for their contribution to this work. J.A.L-D. was supported by the Spanish Ministry of Science through a Juan de la Cierva-Incorporación fellowship and by the Asociación Española Contra el Cáncer (AECC) through an AECC Investigador fellowship. I.M. was funded by an FPI fellowship from the Spanish Ministry of Science. Work in the laboratory of M.S. was funded by the IRB and ‘la Caixa’ Foundation, and by grants from the Spanish Ministry of Science cofunded by the European Regional Development Fund (ERDF) (no. SAF2017-82613-R), European Research Council (no. ERC-2014-AdG/669622) and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282). J.L.K., T.T. and S.C. were supported by the National Institutes of Health (grant nos. R37AG13925, R33AG61456, R01AG072301, R01AG61414, P01AG62413 and UH3AG56933), the Connor Fund, Robert J. and Theresa W. Ryan and the Noaber Foundation. A.G. received funding from the Spanish Ministry of Science cofunded by the ERDF (no. RTC-2017-6123-1), from the Instituto de Salud Carlos III (no. MS15/00058) and from CAIMI-II (grant no. 53/2021) supported by the BBVA Foundation. A.G.-G. was the recipient of a PERIS grant (no. SLT017/20/000131) from the Generalitat de Catalunya. The laboratory of M. Abad received funding from the Spanish Ministry of Science and Innovation (nos. RTI2018-102046-B-I00A and RTC-2017-6123-1) and the AECC (no. PRYCO211023SERR). M.A. was the recipient of a Ramón y Cajal contract from the Spanish Ministry of Science and Innovation (no. RYC-2013-14747). O.B. was the recipient of a FPIAGAUR fellowship from Generalitat de Catalunya. Work in the laboratory of J.A. is supported by the Breast Cancer Research Foundation (no. BCRF-21-008), Instituto de Salud Carlos III (project refs. AC15/00062, CB16/12/00449 and PI19/01181) and the European Commission (under the Framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER), AECC and Fundació La Caixa (no. HR22-00776).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

  • Nadal Serrano, Mercedes
  • Morancho Armisen, Beatriz
  • Escriva de Romaní Muñoz, Santiago Ignacio
  • Luque García, Antonio
  • Espinosa Bravo, Martin
  • Peg Camara, Vicente
  • Cortés Castan, Javier
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
  • Saura Manich, Cristina
  • Escorihuela Baez, Marta
T-DM1; Conjugat anticòs-fàrmac; Càncer de mama, T-DM1; Conjugado anticuerpo-fármaco; Cáncer de mama, T-DM1; Antibody-drug conjugate; Breast cancer, Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy, primary or acquired resistance frequently develops, particularly in advanced stages of the disease. Second generation ADCs targeting HER2 are meant to supersede T-DM1 by using a cleavable linker and a more potent payload with a different mechanism of action. To determine the effect of one of these novel ADCs, SYD985, on tumors resistant to T-DM1, we developed several patient-derived models of resistance to T-DM1. Characterization of these models showed that previously described mechanisms—HER2 downmodulation, impairment of lysosomal function and upregulation of drug efflux pumps—account for the resistances observed, arguing that mechanisms of resistance to T-DM1 are limited, and most of them have already been described. Importantly, SYD985 was effective in these models, showing that the resistance to first generation ADCs can be overcome with an improved design., This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Fundación Mutua Madrileña, Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer. BM is supported by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). JZ is supported by a fellowship from China Scholarship Council (CSC). JA is supported by Institució Catalana de Recerca i Estudis Avançats.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

  • Nadal Serrano, Mercedes
  • Lalinde-Gutiérrez, Marta
  • Morancho Armisen, Beatriz
  • Pérez-Ramos, Sandra
  • Escriva de Romaní Muñoz, Santiago Ignacio
  • Gandullo Sánchez, Lucía
  • Cortés Castan, Javier
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
  • Arenas Lahuerta, Enrique Javier
  • Saura Manich, Cristina
  • Escorihuela Baez, Marta
  • Duro Sánchez, Santiago
  • Rodilla Benito, Verónica
Eficàcia; Conjugats de fàrmacs; Càncer de mama, Eficacia; Conjugados de medicamentos; Cáncer de mama, Efficacy; Drug conjugates; Breast cancer, Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression. Significance: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells., This work was supported by Breast Cancer Research Foundation (BCRF-20-008), Instituto de Salud Carlos III (project reference numbers AC15/00062, CB16/12/00449 and PI19/01181), the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Fundación Mutua Madrileña and Asociación Española Contra el Cáncer. S. Duro-Sánchez is supported by the Spanish Ministerio de Universidades by the grant Formación de Profesorado Universitario (FPU20/05388). A. Esteve-Codina is funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER. The authors acknowledge Alyson MacInnes for reviewing and editing the article.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

  • Nadal-Serrano, Mercedes|||0000-0002-1299-495X
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Luque, Antonio
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Peg, Vicente|||0000-0002-5203-6166
  • Dijcks, Fred A.|||0000-0002-6023-9422
  • Dokter, Wim .H.A.
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy, primary or acquired resistance frequently develops, particularly in advanced stages of the disease. Second generation ADCs targeting HER2 are meant to supersede T-DM1 by using a cleavable linker and a more potent payload with a different mechanism of action. To determine the effect of one of these novel ADCs, SYD985, on tumors resistant to T-DM1, we developed several patient-derived models of resistance to T-DM1. Characterization of these models showed that previously described mechanisms-HER2 downmodulation, impairment of lysosomal function and upregulation of drug efflux pumps-account for the resistances observed, arguing that mechanisms of resistance to T-DM1 are limited, and most of them have already been described. Importantly, SYD985 was effective in these models, showing that the resistance to first generation ADCs can be overcome with an improved design.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation

  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Rius Ruiz, Irene|||0000-0002-6097-7572
  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Luque, Antonio
  • Fajardo, Carlos Alberto
  • Gros, Alena
  • Klein, Christian|||0000-0001-7594-7280
  • Arribas, Joaquín V|||0000-0002-0504-0664
Immunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these active cytotoxic cells are correctly engaged to cancer cells, they will unfailingly eliminate the latter, provided that inhibitory factors are in check. T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) offer an opportunity to test this assumption. Using TCB and CARs directed against HER2, here we show that disruption of interferon-gamma signaling confers resistance to killing by active T lymphocytes. The kinase JAK2, which transduces the signal initiated by interferon-gamma, is a component repeatedly disrupted in several independently generated resistant models. Our results unveil a seemingly widespread strategy used by cancer cells to resist clearance by redirected lymphocytes. In addition, they open the possibility that long-term inhibition of interferon-gamma signaling may impair the elimination phase of immunoediting and, thus, promote tumor progression. Several mechanisms of resistance to T cell-engaging therapies have been described for solid tumors. Here, by using T cell bispecific antibodies and chimeric antigen receptors (CAR) T cells targeting HER2, the authors show that cancer cell intrinsic disruption of interferon-gamma signalling, including downregulation of JAK2, confers resistance to T-cell mediated cytotoxicity
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • Adam-Artigues, Anna|||0000-0002-4257-8535
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Cervera Vidal, Raimundo|||0000-0002-8213-4058
  • Tormo, Eduardo
  • Hernando Davalillo, Cristina
  • Martínez Martínez, María Teresa|||0000-0003-1312-3555
  • Carbonell Asins, Juan Antonio|||0000-0002-8449-5674
  • Simón, Soraya
  • Poveda Ferriols, Jesús Manuel|||0000-0002-9785-0997
  • Moragón, Santiago|||0000-0001-6490-6977
  • Zazo, Sandra
  • Martínez, Débora
  • Rovira, Ana|||0000-0003-1301-2599
  • Burgués, Octavio|||0000-0002-2471-5516
  • Rojo, Federico|||0000-0001-9989-0290
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Bermejo, Begoña
  • Lluch, Ana|||0000-0003-2766-407X
  • Prat, Aleix|||0000-0003-2377-540X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Eroles, Pilar|||0000-0003-2708-6206
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer. AXL is a prognostic biomarker and a potential therapeutic target to restore trastuzumab response in HER2 + breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

  • Gámez-Chiachio, Manuel
  • Molina-Crespo, Ángela
  • Ramos-Nebot, Carmen
  • Martinez-Val, Jeannette
  • Martinez, Lidia
  • Gassner, Katja
  • Llobet, Francisco J.
  • Soriano, Mario
  • Hernandez, Alberto
  • Cordani, Marco
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Diaz, Eva
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Triviño, Juan Carlos
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Llobet Navas, David|||0000-0003-1443-7003
  • Sarrió, David
  • Moreno-Bueno, Gema
Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. Different in vitro approaches (immunoblot, qRT-PCR, flow cytometry, proteomic analysis, immunoprecipitation, and confocal/electron microscopy) were performed in HER2 breast and gastroesophageal carcinoma cell models. Results were then validated using in vivo preclinical animal models and analyzing human breast and gastric cancer samples. GSDMB up-regulation renders HER2 cancer cells more resistant to anti-HER2 agents by promoting protective autophagy. Accordingly, the combination of lapatinib with the autophagy inhibitor chloroquine increases the therapeutic response of GSDMB-positive cancers in vitro and in zebrafish and mice tumor xenograft in vivo models. Mechanistically, GSDMB N-terminal domain interacts with the key components of the autophagy machinery LC3B and Rab7, facilitating the Rab7 activation during pro-survival autophagy in response to anti-HER2 therapies. Finally, we validated these results in clinical samples where GSDMB/Rab7/LC3B co-expression associates significantly with relapse in HER2 breast and gastric cancers. Our findings uncover for the first time a functional link between GSDMB over-expression and protective autophagy in response to HER2-targeted therapies. GSDMB behaves like an autophagy adaptor and plays a pivotal role in modulating autophagosome maturation through Rab7 activation. Finally, our results provide a new and accessible therapeutic approach for HER2/GSDMB + cancers with adverse clinical outcome. The online version contains supplementary material available at 10.1186/s13046-022-02497-w.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized mice

  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Ovejero Romero, Pablo|||0000-0002-6891-9043
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Arenas, Enrique J.|||0000-0001-7076-2666
Immunotherapy has revolutionized cancer treatment, but preclinical models are required to understand immunotherapy resistance mechanisms underlying patient relapse. This protocol describes how to generate an acquired resistance humanized in vivo model to immunotherapies in patient-derived xenografts (PDX). We detail steps to inject human CD34 + cells into NSG mice, followed by generation of immunoresistant PDX in humanized mice. This approach recapitulates the human immune system, allowing investigators to generate preclinical resistance models to different immunotherapies for identifying the resistant phenotype. For complete details on the use and execution of this protocol, please refer to and . Publisher's note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. Immunotherapy has revolutionized cancer treatment, but preclinical models are required to understand immunotherapy resistance mechanisms underlying patient relapse. This protocol describes how to generate an acquired resistance humanized in vivo model to immunotherapies in patient-derived xenografts (PDX). We detail steps to inject human CD34 + cells into NSG mice, followed by generation of immunoresistant PDX in humanized mice. This approach recapitulates the human immune system, allowing investigators to generate preclinical resistance models to different immunotherapies for identifying the resistant phenotype.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Nadal-Serrano, Mercedes|||0000-0002-1299-495X
  • Lalinde-Gutiérrez, Marta|||0000-0002-9858-8775
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Gandullo-Sánchez, Lucía|||0000-0002-7841-230X
  • Pandiella, Atanasio|||0000-0002-4704-8971
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Rodilla, Verónica|||0000-0003-0512-4179
  • Dijcks, Fred A.|||0000-0002-6023-9422
  • Dokter, Wim .H.A.
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression. SIGNIFICANCE: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer

  • Palafox, Marta|||0000-0002-1762-3250
  • Monserrat, Laia|||0000-0002-8802-3033
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ibrahimi, Nusaibah|||0000-0003-4537-0323
  • Kannan, Srinivasaraghavan|||0000-0002-9539-5249
  • Mina, Leonardo
  • Herrera-Abreu, Maria Teresa
  • Òdena, Andreu|||0000-0003-1529-880X
  • Sánchez Guixé, Mònica|||0000-0002-9430-4413
  • Capelán, Marta
  • Azaro, Analía
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Grueso, Judit|||0000-0003-1093-7940
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Su, Faye
  • Lin, Kui
  • Clarke, Robert B.|||0000-0001-5407-3123
  • Caldas, Carlos|||0000-0003-3547-1489
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Michiels, Stefan|||0000-0002-6963-2968
  • García-Sanz, Alicia
  • Turner, Nicholas C.|||0000-0001-8937-0873
  • Prat, Aleix|||0000-0003-2377-540X
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Verma, Chandra S.
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Arnedos, Monica
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Serra, Violeta|||0000-0001-6620-1065
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra, Violeta|||0000-0001-6620-1065
  • Wang, Anderson T.|||0000-0002-3571-5095
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Polanska, Urszula|||0000-0003-1017-594X
  • Palafox, Marta|||0000-0002-1762-3250
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Jones, Gemma|||0000-0002-7567-681X
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Armenia, Joshua|||0000-0002-9005-7769
  • Michopoulos, Filippos|||0000-0002-3667-6147
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Brough, Rachel|||0000-0002-1862-7130
  • Gulati, Aditi|||0000-0001-7476-2524
  • Pettitt, Stephen|||0000-0003-3313-3857
  • Bulusu, Krishna C.|||0000-0002-5092-6640
  • Nikkila, Jenni|||0000-0003-1380-8781
  • Wilson, Zena|||0000-0001-8811-4069
  • Hughes, Adina|||0000-0002-5711-627X
  • Wijnhoven, Paul W.G.|||0000-0002-5489-3006
  • Ahmed, Ambar|||0000-0002-5890-5035
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lau, Alan|||0000-0003-1055-9812
  • Critchlow, Susan|||0000-0002-4647-8988
  • Dougherty, Brian|||0000-0002-0093-1142
  • Caldas, Carlos|||0000-0003-3547-1489
  • Mills, Gordon|||0000-0002-0144-9614
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Forment, Josep V.|||0000-0002-7797-2583
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Lord, Christopher J.|||0000-0002-3226-0515
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • O'Connor, Mark J.|||0000-0003-1823-625X
PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. We analyzed breast and ovarian patientderived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

  • Chaib, Selim
  • Lopez-Dominguez, Jose Alberto
  • Lalinde Gutiérrez, Marta
  • Prats, Neus
  • Marin Guillen, Ines
  • Boix Sánchez, Olga
  • Pérez Ramos, Sandra
  • Escorihuela Baez, Marta
  • Garcia-Garijo, Andrea
  • Abad, Maria
  • Gros, Alena
  • Arribas, Joaquin
Chemotherapy; Intratumoral senescent cells, Quimioterapia; Células senescentes intratumorales, Quimioteràpia; Cèl·lules senescents intratumorals, Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence., We thank the IRB Core Facilities (Functional Genomics Core, Biostatistics/Bioinformatics and Histopathology), the Parc Científic de Barcelona Animal Facility and the University of Barcelona/Centros Científicos y Tecnológicos de la Universidad de Barcelona Flow Cytometry Facility for their contribution to this work. J.A.L-D. was supported by the Spanish Ministry of Science through a Juan de la Cierva-Incorporación fellowship and by the Asociación Española Contra el Cáncer (AECC) through an AECC Investigador fellowship. I.M. was funded by an FPI fellowship from the Spanish Ministry of Science. Work in the laboratory of M.S. was funded by the IRB and ‘la Caixa’ Foundation, and by grants from the Spanish Ministry of Science cofunded by the European Regional Development Fund (ERDF) (no. SAF2017-82613-R), European Research Council (no. ERC-2014-AdG/669622) and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282). J.L.K., T.T. and S.C. were supported by the National Institutes of Health (grant nos. R37AG13925, R33AG61456, R01AG072301, R01AG61414, P01AG62413 and UH3AG56933), the Connor Fund, Robert J. and Theresa W. Ryan and the Noaber Foundation. A.G. received funding from the Spanish Ministry of Science cofunded by the ERDF (no. RTC-2017-6123-1), from the Instituto de Salud Carlos III (no. MS15/00058) and from CAIMI-II (grant no. 53/2021) supported by the BBVA Foundation. A.G.-G. was the recipient of a PERIS grant (no. SLT017/20/000131) from the Generalitat de Catalunya. The laboratory of M. Abad received funding from the Spanish Ministry of Science and Innovation (nos. RTI2018-102046-B-I00A and RTC-2017-6123-1) and the AECC (no. PRYCO211023SERR). M.A. was the recipient of a Ramón y Cajal contract from the Spanish Ministry of Science and Innovation (no. RYC-2013-14747). O.B. was the recipient of a FPIAGAUR fellowship from Generalitat de Catalunya. Work in the laboratory of J.A. is supported by the Breast Cancer Research Foundation (no. BCRF-21-008), Instituto de Salud Carlos III (project refs. AC15/00062, CB16/12/00449 and PI19/01181) and the European Commission (under the Framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER), AECC and Fundació La Caixa (no. HR22-00776).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • ADAM-ARTIGUES, ANNA
  • Brasó-Maristany, Fara
  • Cervera Vidal, Raimundo
  • Tormo, Eduardo
  • Arribas López, Joaquin Vicente
  • Arenas Lahuerta, Enrique Javier
  • Martínez-Sabadell, Alex
Breast cancer; Heterodimerization, Cáncer de mama; Heterodimerización, Càncer de mama; Heterodimerització, Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer., A.A.-A., E.J.A., and F.B.-M. were supported by Asociación Española contra el Cáncer AECC (PRDVA18013LLUC to A.A.-A., POSTD211413AREN to E.J.A., and AECC_Postdoctoral17-1062 to F.B.-M.). A.M.-S. was funded by the Spanish Government (PFIS FI20/00188). J.Ar. is supported by Breast Cancer Research Foundation (BCRF-20-08), Instituto de Salud Carlos III Project reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (AECC). A.P. was supported by Instituto de Salud Carlos III—PI19/01846, Breast Cancer Now—2018NOVPCC1294. P.E. and A.L. were funded by Instituto de Salud Carlos III and cofinanced by FEDER (PI18/01219 to P.E. and CB16/12/00481 to A.L.). J.M.C. was funded by Sociedad Española de Oncología Médica (Rio Hortega-SEOM) and Compromiso ADAMED.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

  • Nadal Serrano, Mercedes
  • Morancho Armisen, Beatriz
  • Escriva de Romaní Muñoz, Santiago Ignacio
  • Luque García, Antonio
  • Espinosa Bravo, Martin
  • Peg Camara, Vicente
  • Cortés Castan, Javier
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
  • Saura Manich, Cristina
  • Escorihuela Baez, Marta
T-DM1; Conjugat anticòs-fàrmac; Càncer de mama, T-DM1; Conjugado anticuerpo-fármaco; Cáncer de mama, T-DM1; Antibody-drug conjugate; Breast cancer, Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy, primary or acquired resistance frequently develops, particularly in advanced stages of the disease. Second generation ADCs targeting HER2 are meant to supersede T-DM1 by using a cleavable linker and a more potent payload with a different mechanism of action. To determine the effect of one of these novel ADCs, SYD985, on tumors resistant to T-DM1, we developed several patient-derived models of resistance to T-DM1. Characterization of these models showed that previously described mechanisms—HER2 downmodulation, impairment of lysosomal function and upregulation of drug efflux pumps—account for the resistances observed, arguing that mechanisms of resistance to T-DM1 are limited, and most of them have already been described. Importantly, SYD985 was effective in these models, showing that the resistance to first generation ADCs can be overcome with an improved design., This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Fundación Mutua Madrileña, Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer. BM is supported by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). JZ is supported by a fellowship from China Scholarship Council (CSC). JA is supported by Institució Catalana de Recerca i Estudis Avançats.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

  • Nadal Serrano, Mercedes
  • Lalinde-Gutiérrez, Marta
  • Morancho Armisen, Beatriz
  • Pérez-Ramos, Sandra
  • Escriva de Romaní Muñoz, Santiago Ignacio
  • Gandullo Sánchez, Lucía
  • Cortés Castan, Javier
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
  • Arenas Lahuerta, Enrique Javier
  • Saura Manich, Cristina
  • Escorihuela Baez, Marta
  • Duro Sánchez, Santiago
  • Rodilla Benito, Verónica
Eficàcia; Conjugats de fàrmacs; Càncer de mama, Eficacia; Conjugados de medicamentos; Cáncer de mama, Efficacy; Drug conjugates; Breast cancer, Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression. Significance: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells., This work was supported by Breast Cancer Research Foundation (BCRF-20-008), Instituto de Salud Carlos III (project reference numbers AC15/00062, CB16/12/00449 and PI19/01181), the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Fundación Mutua Madrileña and Asociación Española Contra el Cáncer. S. Duro-Sánchez is supported by the Spanish Ministerio de Universidades by the grant Formación de Profesorado Universitario (FPU20/05388). A. Esteve-Codina is funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER. The authors acknowledge Alyson MacInnes for reviewing and editing the article.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

  • Gámez‑Chiachio, Manuel
  • Molina‑Crespo, Ángela
  • Ramos Nebot, Carmen
  • Martinez‑Val, Jeannette
  • Martinez, Lidia
  • Gassner, Katja
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
Gasdermin B; HER2 breast cancer; Protective autophagy, Gasdermin B; Càncer de mama HER2; Autofàgia protectora, Gasdermin B; Cáncer de mama HER2; Autofagia protectora, Background Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. Methods Different in vitro approaches (immunoblot, qRT-PCR, flow cytometry, proteomic analysis, immunoprecipitation, and confocal/electron microscopy) were performed in HER2 breast and gastroesophageal carcinoma cell models. Results were then validated using in vivo preclinical animal models and analyzing human breast and gastric cancer samples. Results GSDMB up-regulation renders HER2 cancer cells more resistant to anti-HER2 agents by promoting protective autophagy. Accordingly, the combination of lapatinib with the autophagy inhibitor chloroquine increases the therapeutic response of GSDMB-positive cancers in vitro and in zebrafish and mice tumor xenograft in vivo models. Mechanistically, GSDMB N-terminal domain interacts with the key components of the autophagy machinery LC3B and Rab7, facilitating the Rab7 activation during pro-survival autophagy in response to anti-HER2 therapies. Finally, we validated these results in clinical samples where GSDMB/Rab7/LC3B co-expression associates significantly with relapse in HER2 breast and gastric cancers. Conclusion Our findings uncover for the first time a functional link between GSDMB over-expression and protective autophagy in response to HER2-targeted therapies. GSDMB behaves like an autophagy adaptor and plays a pivotal role in modulating autophagosome maturation through Rab7 activation. Finally, our results provide a new and accessible therapeutic approach for HER2/GSDMB + cancers with adverse clinical outcome., This study has been supported by the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (PID2019-104644RB-I00) -GMB-, the Instituto de Salud Carlos III (CIBERONC, CB16/12/00449 -JA-, CB16/12/00231 -DLN- and CB16/12/00295 -GMB-, PI19/01181 -JA-, PI18/00795, CP17/00063 and RTI2018-095611-A-I00 -DLN- and ERA-NET TRANSCAN-2 -JA- [all partly supported by FEDER funds]) and by the AECC Scientific Foundation (FC_AECC PROYE19036MOR -GMB- and LABAE19004LLOB -DLN-). Furthermore, this work was supported by Breast Cancer Research Foundation (BCRF-19–08) -JA-. We are also grateful to the CERCA Programme (Generalitat de Catalunya) for institutional support. MGC and DS contracts are funded by CIBERONC, KG is a recipient of a PFIS fellowship (FI19/00188), RRB is recipient of a Ramón y Cajal grant (RyC-2016–19671) and DLN is recipient of a Miguel Servet grant (MS17/00063) (all partly supported by FEDER funds). We are also grateful to MD Anderson BIOBANK for providing tumor samples. The bank (reference # B.0000745) belongs to the National Registry of Biobanks coordinated by the Carlos III Health Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.